POPULARITY
9 episodes with cell free
3 episodes with cell free
2 episodes with cell free
2 episodes with cell free
3 episodes with cell free
2 episodes with cell free
2 episodes with cell free
2 episodes with cell free
2 episodes with cell free
The 2024 winners of the March of Dimes Basil O'Connor Starter Scholar Research Awards, Dr. Elizabeth Enninga and Dr. Mara Murray Horwitz, discuss their areas of study. Dr. Enninga, an Assistant Professor of Obstetrics & Gynecology, and Immunology, at Minnesota's Mayo Clinic, explains how cell free (cf) fetal DNA triggers labor and preterm birth, and how understanding more about this process can help prevent early labor and more effectively induce labor. Dr. Murray Horwitz, a primary care doctor at Boston Medical Center and an assistant professor of medicine at Boston University, discusses barriers women with a hypertensive disorder of pregnancy (HDP), like preeclampsia, face in achieving cardiac and overall health after childbirth, and delves into an intervention called patient navigation that can lessen those barriers.
Host: Denise M. Dupras, M.D., Ph.D. Guest: Aaron S. Mansfield, M.D. Can a simple blood draw diagnose cancer? Join this episode of Genes & Your Health with Aaron Mansfield, M.D., a Mayo Clinic medical oncologist whose focus is on thoracic malignancies and early therapeutics, as we discuss the science behind non-invasive cancer screening, how cell-free DNA tests can help diagnose some cancers earlier than ever before, what limitations exist, and what promise the future holds. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
Dr. Medhat Askar joins the podcast to discuss the utility and validation of donor-derived cell-free DNA (dd-cfDNA) testing for solid-organ recipients. Dr. Askar also discusses the regulatory status of dd-cfDNA in the United States.
A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, reported his group's validation of the test that assesses the pattern of circulating fragments of tumor DNA, known as fragmentomes. After discussing the findings at an AACR press briefing, Velculescu joined Peter Goodwin in the OncTimesTalk podcast studio to discuss the clinical implications.
We're joined by FabricNano CEO & Co-Founder Grant Aarons to learn about how they're transforming the industrial chemical process using cell-free biomanufacturing.This new biomanufacturing method has many benefits, it requires less resources and energy to maintain and produce less waste than the traditional cell-based approach.Hosted by Bruce BratleyFeaturing Grant Aarons
Experts from Indivumed Services answer questions from webinar where they describe the role of longitudinal plasma samples for cancer research.
Episode Description: We reflect on our first year of podcasting and share some of the things we learned, enjoyed, and appreciated about biotech. We discuss some of the themes and topics that emerged from our conversations with biotech leaders, such as the complexity and diversity of biology, the challenges and opportunities of scaling bioproduction, and the importance of radical thinking and innovation. We also highlight some of our favorite episodes and guests, and thank our listeners for their support and feedback. Join us as we celebrate one year of growing everything! Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space. Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00:00 - Opening Insights: A Year in Biotech Podcasting 00:01:03 - Behind the Scenes: Engaging with Our Biotech Community 00:03:20 - Key Takeaways: What Biotech Taught Us This Year 00:05:56 - Deep Dive: The Promise of Terraformation in Biotech 00:08:19 - The Essence of Biotech: Unraveling Biological Complexity 00:09:03 - Microbial Marvels: Their Crucial Role in Biotechnology 00:13:19 - Fan Favorites: Highlighting Top Episodes & Guests 00:16:20 - Scaling Up: Tackling Biotech's Biggest Challenges 00:21:25 - Forward-Thinking: The Future of Biotech & Our Podcast 00:23:33 - Gratitude and Goodbyes: A Special Thanks to Our Listeners Episode Links: 51. Cell-Free, Problem-Free: Enzyme Alchemy with Alex Rosay at Cascade Biocatalysts 48. Belly of the Beast: How BiomEdit's Aaron Schacht Cashes in on Animal Microbiomes for Health & Profit 43. Emission Impossible: Lanzatech's Zara Summers on Converting Carbon into Cash 49. From Edibles to Medicals: Jellatech's Stephanie Michelsen Uncovers the Multiple Uses of Collagen & Gelatin 27. Charting the Unexplored Microverse for Biological Gold with CULTIVARIUM's Nili Ostrov 25. From Lab to Table: Meat Orbillion's Better-For-You Beef 21. The Venn Diagram of Climate and Biology is a Circle: Kristin Ellis of Lowercarbon Capital 20. The Butterfly Effect: Sustainable High-Performance Materials from Micro-Algae 14. Cannabis & Biotech. Nuff Said. 54. Money, Molecules, and Mind-Benders: Seth Yakatan Returns, Nuff Said 5. Dreaming in Biology: Tales from the Ginkgo Bioworks Studio Have a question or comment? Message us here: Text or Call (804) 505-5553 Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message
Episode Description: Alex Rosay of Cascade Biocatalysts joins us as we delve into the groundbreaking realm of enzyme technology and its transformative impact on various industries. We navigate through the innovative world of cell-free biotechnological solutions, highlighting how these advancements are revolutionizing traditional fermentation processes and offering more sustainable, efficient alternatives. We explore the diverse applications of enzymes, from food ingredients to bio-mining, and the challenges and triumphs in stabilizing these biological catalysts. This episode is a fascinating journey into the heart of biotech innovation, showcasing how nature-inspired solutions are shaping a more sustainable industrial future. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space. Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00 - Meet Alex Rosay and Dive into Enzyme Technology 00:07:48 - The Game-Changing Innovation: Cell-Free Biomanufacturing 00:10:43 - How Biology is Revolutionizing Industries Worldwide 00:11:26 - Insights from Zymergen's Success and Navigating Office Dynamics 00:16:04 - Learning from Zymergen Challenges: Building Stronger Biotech Businesses 00:20:56 - The Scale of Cell-Free Biology: Transforming Manufacturing 00:23:00 - Industry Perspectives on Enhancing Biotech Startups 00:28:30 - Inside Biotech Innovation: Enzyme Production and Stability 00:31:00 - Pioneering Green Technologies: The Next Decade in Biotech 00:36:43 - The Enzymatic Future: Biotech's Role in Brewing and Beyond 00:40:00 - Navigating Startup Challenges: Intellectual Property and Market Competition 00:44:15 - Biological Innovation: Green Materials and Sustainable Industries 00:46:30 - Peering into the Biotech Landscape: Predicting the Next Three Years 00:49:00 - Behind the Scenes: Research and Development in Biotech 00:51:15 - Shaping Traditional Manufacturing with the Power of Biology 00:53:45 - Biotech's Impact on Environmental Sustainability in the Real World Episode Links: LinkedIn Cascade Biocatalysts Have a question or comment? Message us here: Text or Call (804) 505-5553 Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.01.23.525177v1?rss=1 Authors: Zuidema, D., Jones, A., Song, W.-H., Zigo, M., Sutovsky, P. Abstract: The degradation of sperm-borne mitochondria after fertilization is a conserved event. This process known as post-fertilization sperm mitophagy, ensures exclusively maternal inheritance of the mitochondria harbored mitochondrial DNA genome. This mitochondrial degradation is in part carried out by the ubiquitin proteasome system. In mammals, ubiquitin-binding pro-autophagic receptors such as SQSTM1 and GABARAP have also been shown to contribute to sperm mitophagy. These systems work in concert to ensure the timely degradation of the sperm-borne mitochondria after fertilization. We hypothesize that other receptors, cofactors, and substrates are involved in post-fertilization mitophagy. Mass spectrometry was used in conjunction with a porcine cell-free system to identify other autophagic cofactors involved in post-fertilization sperm mitophagy. This porcine cell-free system is able to recapitulate early fertilization proteomic interactions. Altogether, 185 proteins were identified as statistically different between control and cell-free treated spermatozoa. Six of these proteins were further investigated, including MVP, PSMG2, PSMA3, FUNDC2, SAMM50, and BAG5. These proteins were phenotyped using porcine in vitro fertilization, cell imaging, proteomics, and the porcine cell-free system. The present data confirms the involvement of known mitophagy determinants in the regulation of mitochondrial inheritance and provides a master list of candidate mitophagy co-factors to validate in the future hypothesis-driven studies. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Pinpointing someone's risk to develop dementia or frailty may rely on a blood test looking for cell free DNA, a Johns Hopkins study finds. Lolita Nidadavolu, a geriatrics expert and researcher, says this type of DNA provokes a reaction in … Cell free DNA in someone's blood could have many consequences, Elizabeth Tracey reports Read More »
Higher levels of DNA found circulating in the blood of older people were associated with a higher risk for dementia and frailty, a Johns Hopkins study shows. Peter Abadir, a geriatrics expert at Johns Hopkins and one author of the … If cell free DNA is associated with dementia risk, would removing it help? Elizabeth Tracey reports Read More »
Macquarie Correctional Centre Governor Brad Peebles told Ray Hadley he was sceptical about the innovative prison at first, admitting he thought the Commissioner was "stark-raving mad".See omnystudio.com/listener for privacy information.
Dr Philip Smith, Digital and Education Editor of Gut and Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK, interviews Dr Maria Arechederra, young researcher at the Hepatology Program in the Center for Applied Medical Research (CIMA) from the University of Navarra in Pamplona, Spain, on the paper "Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures" which is published in paper copy in Gut in June 2022, and available online: https://gut.bmj.com/content/71/6/1141 Please subscribe to the Gut Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest podcast every month. If you enjoy our podcast, please consider leaving us a review or a comment on the Gut Podcast iTunes page (https://podcasts.apple.com/gb/podcast/gut-podcast/id330976727).
Amir Goldkorn describes translational findings from a phase 2 bladder trial.
Dr. Iyad Alnahhas interviews Dr. Matthias Karajannis about his and his team's recent manuscript entitled: "Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult (AYA) brain tumor patients", published in Neuro-Oncology in February 2022
Dr. Iyad Alnahhas interviews Dr. Carl Koschmann about his and his team's recent manuscript entitled: "Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma" published online in Neuro-Oncology in February 2022. Read the Study
Dr. Fernando Guzman talks with us about Cell-free systems, a method for producing proteins without the laborious process of growing and harvesting cells. One of the main drawbacks of these cell-free systems is the cost, Dr. Guzman shared with us his research in trying to make these systems less expensive and thus more available in low and middle income countries. The benefit of this would be using these methods for disease diagnosis, and also for education purposes where resources are usually limited. To find out more view Dr. Guzman's original research here: https://doi.org/10.1021/acssynbio.1c00342
Michael Jewett is the Charles Deering McCormick Professor of Teaching Excellence, a Professor of Chemical & Biological Engineering, & Co-Director of the Center for Synthetic Biology @ Northwestern University. He is also an Institute Fellow at the Northwestern Argonne Institute for Science & Engineering. Jewett's lab seeks to re-conceptualize the way we engineer complex biological systems for compelling applications in medicine, materials, and energy by transforming biochemical engineering with synthetic biology. Dr. Jewett is the recipient of the NIH Pathway to Independence Award in 2009, David and Lucile Packard Fellowship in Science and Engineering in 2011, the DARPA Young Faculty Award in 2011, the Agilent Early Career Professor Award in 2011, the 3M non-tenured faculty grant in 2012, the Camille-Dreyfus Teacher-Scholar Award in 2015, the ACS Biochemical Technologies Division Young Investigator Award in 2017, and the Biochemical Engineering Journal Young Investigator Award in 2018.w/ Special Guest Host: David MaceDavid Mace is Co-founder & CEO @ SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge. Previously David was an Entrepreneur in Residence at 8VC, where he focused on the intersection of biology & computer science. He is a graduate of the California Institute of Technology.SwiftScale Biologics (@SwiftScaleBio) seeks to bring life-saving drugs to patients faster than previously possible. Specifically, SwiftScale uses cutting-edge cell-free and bacterial production platforms to rapidly produce protein therapeutics. SwiftScale's technology is faster and cheaper than traditional manufacturing approaches, reducing time and cost to reach clinical trials and market. In Dec 2021, National Resilience acquired SwiftScale. Resilience is a technology focused manufacturing company dedicated to broadening access to complex medicines.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)
Covering the successes of those who stood and won is a good thing. Here we have a couple more examples of those who stood tall. But then there is the projection of where we are heading. In the same way it was clear back in 2013 that an endgame would follow, we now cover that (more...) The post 374.5- Some Legal Successes and the End of Wealth via Crypto + Cell (Free) appeared first on Crrow777 Radio.
In this episode, we are privileged to feature the amazing Dr. Paul Billings. Paul is the Chief Medical Officer and Senior Vice president of Medical Affairs for Natera. Natera is a global leader in cell-free (cfDNA) testing with a focus on women's health, oncology, and organ health. The company is an expert at the process and measurement of cell-free DNA and at providing that in context with genetic information as well. Dr. Billings educates us on cell-free (cfDNA) testing. He discusses how his company develops millions of testing opportunities in genetics that have given them incredible expertise in measuring very small amounts of cell-free DNA. He shares how Natera has developed a series of products to cast light on things like the health of a fetus, recurrence of cancer, and health of an organ transplant. Dr.l also shares his hypothesis on how a drug post organ transplant is working through constant monitoring of cfDNA. He talks about the three indications Natera is working on, providing clear explanations of how they add enormous value to genetics and healthcare, and specific examples of how Natera works. There are so many things to learn from this insightful and exciting conversation with Paul, so please tune in! Click this link to the show notes, transcript, and resources: outcomesrocket.health
Britney is FREE, finally. IN this special episode Laura is joined by legal expert and former LA prosecutor Loni Coombs who was at the courthouse today for this historical ruling by Judge Brenda Penny. We discuss what went on and some of the questions that still must be asked. You won't want to miss this. #FreedBritney #BritneySpears #Women Matter #Trauma #Misogyny #Conservatorship #CoerciveControl #MaleViolence #Podcast #TrueCrime #CrimeAnalyst Clips https://twitter.com/variety/status/1459288536192991236?s=21 https://twitter.com/variety/status/1459289504662147079?s=21 Sources https://www.rollingstone.com/music/music-news/britney-spears-ex-managers-fight-document-request-deny-listening-device-1254016/ Leave a Review If you want to support my work and Crime Analyst and if you enjoyed this episode, please leave a 5-star review here: https://www.crime-analyst.com/reviews/new/
To claim credit for this episode, visit: Mayo Clinic Talks Podcast: Genes & Your Health Guests: Minetta C. Liu, M.D.; Myra J. Wick, M.D., Ph.D. (@MyraWickMD) Host: Denise M. Dupras, M.D., Ph.D. What is cell-free DNA? How does this type of DNA interact with our body? How is it useful in the clinical setting? Advances in technologies has expanded our understanding of cell-free DNA and its implications. Where are we now and what can we look for in the future? Find out these answers and more in the seventh episode of the Genes & Your Health miniseries from the Center for Individualized Medicine. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
In this episode, we have the privilege of hosting the amazing Steve Chapman, Chief Executive Officer at Natera. Natera is a medical technology company specializing in cell-free DNA testing that can detect disease. Steve discusses how his company is elevating the science in the genetic testing space, especially in organ health, women's health, and oncology. He explains several distinctions of Natera's processes from the traditional standard of care and existing traditional biomarkers. He shares his thoughts on current immunotherapy procedures, value-based care, setbacks, and more. Click this link to the show notes, transcript, and resources: outcomesrocket.health
Wireless devices normally connect to a single access point, deployed at one location. The access points are deployed sparsely to create large cell regions, each controlled by the nearest access point. This architecture was conceived for mobile telephony and has been inherited by today’s networks, even if those mainly transfer wireless data. However, future wireless networks might be organized entirely differently. In this episode, Erik G. Larsson and Emil Björnson discuss how one can create cell-free networks consisting of distributed massive MIMO arrays. The vision is that each user will be surrounded by small access points that cooperate to provide uniformly high service quality. The conversation covers the key benefits, how the network architecture can be evolved to support the new technology, and what the main research challenges are. To learn more, they recommend the article “Ubiquitous Cell-Free Massive MIMO Communications” (https://jwcn-eurasipjournals.springeropen.com/track/pdf/10.1186/s13638-019-1507-0) and the new book “Foundations of User-Centric Cell-Free Massive MIMO” (https://www.nowpublishers.com/article/Details/SIG-109). Contact us at podcast@ebjornson.com. Music: On the Verge by Joseph McDade. Visit Erik’s website https://liu.se/en/employee/erila39 and Emil’s website https://ebjornson.com/
William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of a private biotechnology company, the Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.
Revée Agyepong is a registered nurse specializing in neonatal intensive care and based in Edmonton, Alberta, Canada. She currently works in the Pediatric Hematology Clinic at the Stollery Children’s Hospital as the Sickle Cell Disease Nurse…which is fitting, considering that until recently, she was living with sickle cell disease herself. In late 2017, she received an allogenic stem cell transplant to cure sickle cell anemia, thanks to her sister’s bone marrow donation. After 25 years of hospital admissions and countless treatments, Revée made history as the first adult in Alberta to receive this disease-reversing — and life-changing — treatment. A member of the Not Just You Sickle Cell Transplant Alliance for Research and the Canadian Hemoglobinopathy Nurses Group, Revée is passionate about inspiring, encouraging, supporting, and advocating for the sickle cell community. Come along with her on this beautiful story of perseverance, determination, and faith…and help us congratulate Revée as she has just launched her new business venture, inspired by her health experience…a natural home, hair, and skincare line called Rêve Naturals, designed to help others reduce toxins in their day-to-day! Tune in as Revée shares: what it was like growing up with sickle cell how growing up with chronic illness tested her faith how her treatments developed over time before her remission how her health experiences drew her into a career in medicine how she became the first adult in Alberta to undergo a stem cell transplant to cure sickle cell that her sister was a perfect bone marrow match, and donated for her stem cell treatment that she’s gone from sickle cell patient to transplant patient that she’s officially sickle-cell-free — and that this strangely sent her into a kind of identity crisis that as a transplant patient, she doesn’t fit into the “traditional” model of aftercare support that for her, transplant was a choice — but for most recipients, transplant is the only option how her sister’s advocacy played a role in inspiring her to be a patient advocate how she became expert at playing down her own pain
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.18.255885v1?rss=1 Authors: Zheng, H., Zhu, M. S., Liu, Y. Abstract: Circulating cell-free DNA (cfDNA) is a promising biomarker for the diagnosis and prognosis of many diseases, including cancer. The genome-wide non-random fragmentation pat-terns of cfDNA are associated with the nucleosomal protection, epigenetic environment, and gene expression in the cell types that contributed to cfDNA. However, current progress on the development of computational methods and understanding of molecular mechanisms behind cfDNA fragmentation patterns is significantly limited by the controlled-access of cfDNA whole-genome sequencing (WGS) dataset. Here, we present FinaleDB (FragmentatIoN AnaLysis of cEll-free DNA DataBase), a comprehensive database to host thousands of uniformly processed and curated de-identified cfDNA WGS datasets across different pathological conditions. Furthermore, FinaleDB comes with a fragmentation genome browser, from which users can seamlessly integrate thousands of other omics data in different cell types to experience a comprehensive view of both gene-regulatory landscape and cfDNA fragmentation patterns. Availability and implementation: FinaleDB service: http://finaledb.research.cchmc.org/. FinaleDB source code: https://github.com/epifluidlab/finaledb_portal and https://github.com/epifluidlab/finaledb_workflow. Copy rights belong to original authors. Visit the link for more info
On August 12, 2020, the ACOG released a revised practice bulletin (226) on screening for fetal aneuploidy. In this session we will focus on cell free DNA genetic screening. How should we counsel younger women on this screening tool? Can cell free DNA be used after an abnormal QUAD screen? How is cell free DNA related to maternal malignancy? We will answer these questions and more in this session.
Podcast: Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses Rita Lampignano interviewed by Markus Sprenger-Haussels
In episode 9 we dive deep into the topic that could not be more relevant today - diagnosis of infectious diseases. Our guest on this episode is Tim Blauwkamp, the co-founder and Chief Scientific Officer of Karius, a company that leverages genomics and AI to develop highly-accurate diagnostic tests based on cell-free DNA sequencing. Karius has recently raised a stunning Series B round of $165 million to further the transition of their test to clinic.Tim did his PhD in Biochemistry at the University of Michigan, where he studied genes involved in nitrogen assimilation in bacteria. He then continued as a PostDoc first in Michigan and then at Stanford researching the mechanisms behind WNT signaling and its role in cell differentiation. He then joined Moleculo as a Head of Molecular biology. Moleculo was acquired by Illumina and Tim was responsible for bringing to life the technologies that made it possible to generate long and accurate sequencing reads. About six years ago, Tim co-founded Karius together with Mickey Kertesz. Tim and his team have achieved enormous progress during the last years, bringing the diagnostic tests to clinics that are already changing the lives of patients. Together with Tim, we have talked about:: ◦ The story behind Karius ◦ Cell-free DNA (cfDNA) as a blood biomarker of infection ◦ Why DNA sequencing has an edge over classical microbiology methods ◦ The challenge of isolating microbial cfDNA from blood ◦ Untangling cfDNA sequencing data with AI ◦ Why Coronavirus (SARS-CoV-2) is hard to detect using NGS ◦ Diagnosing sepsis based on microbial cfDNA ◦ Clinical evidence as a key to healthcare innovation ◦ Working with payers to spread the use of innovative diagnostic tests ◦ How cfDNA screening can become a cornerstone of next-generation medicineGet in touch with Tim: ◦ LinkedIn: Tim Blauwkamp ◦ Twitter: @timblauwkamp ◦ Web (Karius): http://kariusdx.com/ ◦ Email: tim.blauwkamp@kariusdx.comMake sure to download the full show notes with our guest's bio, links to their most notable work and our recommendations for further reads on the topic of the episode at pmedcast.com
Javin Oza observed the separation of scientists and engineers on university campuses, at conferences, and in classrooms. Yet he also noted that advances in biochemistry require perspectives from both bioengineers and lab scientists. Oza’s current research aims to bridge the gap between these thought-approaches to bring about advancements in cell-free protein synthesis. He speaks with The Chain about barriers to implementing CFPS, what resources are available for the transition to cell-free systems, and advice for young protein scientists.
The regenerative medicine arena has grown by leaps and bounds these past few years. As the decade draws to a close, we ask the question: what’s the future of regenerative medical procedures? Are stem cell procedures still going to remain the popular choice? Or are we going to see cell-free therapies become the more popular in the coming years? We ask Dr. Milad Riazifar about his thoughts on this topic on this episode of the regenerative warrior podcast. Stay tuned. To find out more about our guest, become a guest on our show, or if you want Dr. Carter present at your event or podcast, learn more about coaching, consulting, allografts, exosomes, supplements, legal help, or how to create a million dollar business card and dominate your area, we’re here to help you. Just text your name and question to 561-962-1231 or go to our website at drrosscarter.com to learn more. Thanks for listening! Please subscribe to be notified of all new episodes. You can also like and share each episode to help us grow!
Over fifty years since its first use, Dr. Marco Casteleijn breaks down the resurgence of cell-free protein synthesis and its application across industries, including VTT’s research of cell-free proteins for pharma and the fashion industry. Plus, we discuss the importance of science writing to describe discoveries and communicate findings with funders and the public.
Bladder cancer is the ninth most common cancer worldwide. The current diagnosis and monitoring of bladder cancer is still heavily reliant on cystoscopy, an invasive procedure where the tumor is directly visualized. However, a paper appearing in the July 2019 issue of Clinical Chemistry from Dr. Dennis Lo’s laboratory in Hong Kong reports that bladder cancer can be detected noninvasively in urinary cell-free DNA by methylomic and copy number analysis. Such analyses could be used as a liquid biopsy to aid in the diagnosis and monitoring of bladder cancer.
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
You have the option to screen for a number of genetic disorders in pregnancy. How are these tests performed and what can be discovered? Dr. Julia Cormano explains the difference between screening and diagnostic testing, what can be learned from a blood test, as well what to expect from chorionic villus sampling and amniocentesis. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 33874]
Dr. Louis Metzger is the Chief Scientific Officer of Tierra Biosciences which is leveraging computation, automation, and cell-free synthetic biology to search for molecules which might otherwise be buried in the complexity of cells’ metabolism to cure disease, enhance food production, identify new antibiotics, etc. Louis is also a Mentor at IndieBio, Civic Partner at Minerva Project, Co-Founder of BioCaptivate, and passed the last 6 years as a Principal Scientist in Infectious Diseases at Novartis, discovering novel antibiotics. https://tierrabiosciences.com Twitter ► https://twitter.com/LouisMetzger_ LinkedIn ► http://bit.ly/LouisLinkedIn ******* Simulation is rebirthing the public intellectual by hosting the greatest multidisciplinary minds of our time. Build the future. Architect the frameworks and resource flows to maximize human potential. http://simulationseries.com ******* SUBSCRIBE TO SIMULATION ► YOUTUBE: http://bit.ly/SimYoTu ITUNES: http://bit.ly/SimulationiTunes INSTAGRAM: http://bit.ly/SimulationIG TWITTER: http://bit.ly/SimulationTwitter ******* FACEBOOK: http://bit.ly/SimulationFB SOUNDCLOUD: http://bit.ly/SimulationSC LINKEDIN: http://bit.ly/SimulationLinkedIn PATREON: http://bit.ly/SimulationPatreon CRYPTO: http://bit.ly/SimCrypto ******* NUANCE-DRIVEN DISCOURSE ► http://bit.ly/SimulationTG WATCH ALLEN'S TEDx TALK ► http://bit.ly/AllenTEDx FOLLOW ALLEN ► INSTAGRAM: http://bit.ly/AllenIG TWITTER: http://bit.ly/AllenT ******* LIST OF THOUGHT-PROVOKING QUESTIONS ► http://simulationseries.com/the-list GET IN TOUCH ► simulationseries@gmail.com
You have several options during your pregnancy when it comes to testing for chromosome abnormalities in your baby. The most common non-invasive screening tests are the first trimester screen and quad screen and these have been offered to all pregnant women for many years. With better technology comes more options for testing, especially when it comes to examining DNA. The cfDNA (cell free DNA) test, which became available in 2011, is named for the fragments of your baby’s DNA that are freely floating in your blood stream. This simple blood test from you can test for many more chromosome abnormalities than the traditional screen tests, plus the sex of your baby and their Rh factor. This episode breaks down everything you need to know about the cfDNA or NIPT test compared to other options so you can decide whether to opt in to this test and how to understand the results. Show Notes: http://pregnancypodcast.com/nipt/ Thank you to Zahler for their support of this episode. Zahler makes a high quality prenatal vitamin that has the active form of folate, that I prefer after all of the research I have read on folic acid, plus it has omega 3s and DHA. This is the prenatal vitamin I take and the one I recommend. Zahler is offering an exclusive discount to listeners of the Pregnancy Podcast. To check out the vitamin and find out how you can save 25% when you buy a one month supply on Amazon go to http://pregnancypodcast.com/vitamin/
Dr. Ryan Corcoran is an assistant professor of medicine at Harvard Medical School and leader of the Corcoran lab at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. R.B. Corcoran and B.A. Chabner. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 2018;379:1754-65.
Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yardwork. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.
How to build a factory to automate processes, Scaling DNA circuits tests to be able to be done in under 30 minutes, why now is the prefect time for Cell Free to exist, a bit...
Editor's Summary by Michael Berkwits, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the August 14, 2018 issue
Dr. Diana Bianchi is from the National Human Genome Research Institute at the NIH in Bethesda, Maryland. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. D.W. Bianchi and R.W.K. Chiu. Sequencing of Circulating Cell-free DNA during Pregnancy. N Engl J Med 2018;379:464-73.
Cell free DNA screening evaluates short segments of DNA in a maternal serum and can be used to screen for fetal aneuploidy, fetal RH type, and sex chromosome abnormalities. In this session, we will review the data on cell free DNA screening from the ACOG practice bulletin number 163.
Cell-free DNA analysis, also called non-invasive prenatal screening and IPS, has emerged as an alternative to the conventional analysis of maternal serum markers. Modern molecular techniques have now achieved sensitivity for the direct detection and analysis of placental DNA fragments that circulate in the maternal bloodstream and serve as a proxy for fetal aneuploidy. This technology is transforming the field of prenatal screening and has significant implications for laboratories, patients, and physicians.
Donor-derived cell-free DNA measurement in the circulating blood of transplant recipients is thought to have utility for clinical monitoring of tissue injury and therefore transplant rejection in heart, lung, liver, and kidney transplants, as increased levels of this biomarker are seen during acute rejection. However, the normal concentration of donor-derived cell-free DNA in successful kidney transplant patients has not been determined. An article titled “Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications” published in the November 2017 issue of JALM, determined the biological variation and reference intervals of this biomarker in this patient population to aid in discrimination between rejection versus no rejection in kidney transplant patients
February 2018 See acast.com/privacy for privacy and opt-out information.
The cell-free fetal DNA test is a relatively new test that may be used to assess the risk of a pregnant woman's developing baby having a chromosome disorder, such as Down syndrome, Edwards syndrome, or Patau syndrome. It may be used to identify other rare conditions resulting from an extra chromosome or missing piece of chromosome.Cell-free fetal DNA is genetic material that is released by the placenta and circulates in a woman's blood during pregnancy. It is present in small quantities starting in the first trimester and increases throughout pregnancy. CffDNA generally reflects the genetic makeup of the developing baby. Sean P. Kenney, MD, with the Center for Maternal & Fetal Care at Bryan Health, is here to help you better understand this procedure and how it can help determine health risks to an unborn child.
Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI. The topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.MolecularDXEurope.com/
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30. Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18. Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.HealthTech.com/Prenatal-Diagnostics/
Extreme sports, extreme eating, extreme weight loss, extreme makeovers, just when you think you've heard it all, how about Extreme PCR?
JALA 19.4 August 2014 A miniaturized array device called Vertical-I with its membrane oriented vertically in reference to the table surface finds a protein synthesis yield 144% higher than that of a horizontal device. Plus, β-glucuronidase reaches the synthesis yield plateau after 2 h versus 4 h. When clogging of membrane pores is confirmed, the Vertical-II is designed to fit into a standard 96-well plate holder, increasing protein expression 406% over the horizontal device and consuming 5 times fewer reagents than a commercial device. To view the article, click here.
Background: Hypermethylation of DNA is an epigenetic alteration commonly found in colorectal cancer (CRC) and can also be detected in blood samples of cancer patients. Methylation of the genes helicase-like transcription factor (HLTF) and hyperplastic polyposis 1 (HPP1) have been proposed as prognostic, and neurogenin 1 (NEUROG1) as diagnostic biomarker. However the underlying mechanisms leading to the release of these genes are unclear. This study aimed at examining the possible correlation of the presence of methylated genes NEUROG1, HLTF and HPP1 in serum with tissue breakdown as a possible mechanism using serum lactate dehydrogenase (LDH) as a surrogate marker. Additionally the prognostic impact of these markers was examined. Methods: Pretherapeutic serum samples from 259 patients from all cancer stages were analyzed. Presence of hypermethylation of the genes HLTF, HPP1, and NEUROG1 was examined using methylation-specific quantitative PCR (MethyLight). LDH was determined using an UV kinetic test. Results: Hypermethylation of HLTF and HPP1 was detected significantly more often in patients with elevated LDH levels (32% vs. 12% {[}p = 0.0005], and 68% vs. 11% {[}p < 0.0001], respectively). Also, higher LDH values correlated with a higher percentage of a fully methylated reference in a linear fashion (Spearman correlation coefficient 0.18 for HLTF {[}p = 0.004]; 0.49 {[}p
This study investigates the adhesion capacity of a polyglycolic acid-(PGA-) hyaluronan scaffold with a structural modification based on a planar polymer (PM) surface in a cadaver cartilage defect model. Two cadaver specimens were used to serially test multiple chondral matrices. In a cadaver hip model, cell free polymer-based cartilage implants with a planar bioinspired PM surface (PGA-PM-scaffolds) were implanted arthroscopically on 10 mm x 15 mm full-thickness femoral hip cartilage lesions. Unprocessed cartilage implants without a bioinspired PM surface were used as control group. The cartilage implants were fixed without and with the use of fibrin glue on femoral hip cartilage defects. After 50 movement cycles and removal of the distraction, a rearthroscopy was performed to assess the outline attachment and integrity of the scaffold. The fixation techniques without and with fibrin fixation showed marginal differences for outline attachment, area coverage, scaffold integrity, and endpoint fixation after 50 cycles. The PGA-PM-scaffolds with fibrin fixation achieved a higher score in terms of the attachment, integrity, and endpoint fixation than the PGA-scaffold on the cartilage defect. Relating to the outline attachment, area coverage, scaffold integrity, and endpoint fixation, the fixation with PGA-PM-scaffolds accomplished significantly better results compared to the PGA-scaffolds (P = 0.03752, P = 0.03078, P = 0.00512, P = 0.00512). PGA-PM-scaffolds demonstrate increased observed initial fixation strength in cadaver femoral head defects relative to PGA-scaffold, particularly when fibrin glue is used for fixation.
Pregnant women identified as high risk based on the prenatal screen can then undergo invasive procedures such as amniocentesis to confirm the diagnosis. Unfortunately, a large number of women with unaffected pregnancies undergo invasive procedures, putting the fetus at unnecessary risk for miscarriage.
Dr. Michael Greene is the Chief of Obstetrics at Massachusetts General Hospital and a Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. S. Morain, M.F. Greene, and M.M. Mello. A New Era in Noninvasive Prenatal Testing. N Engl J Med 2013;369:499-501.
The in vitro proliferation of prokaryotic and eukaryotic cells is remarkably hampered in the presence of heavy water (D2O). Impairment of gene expression at the transcription or translation level can be the base for this effect. However, insights into the underlying mechanisms are lacking. Here, we employ a cell-free expression system for the quantitative analysis of the effect of increasing percentages of D2O on the kinetics of in-vitro GFP expression. Experiments are designed to discriminate the rates of transcription, translation, and protein folding using pDNA and mRNA vectors, respectively. We find that D2O significantly stimulates GFP expression at the transcription level but acts as a suppressor at translation and maturation (folding) in a linear dose-dependent manner. At a D2O concentration of 60%, the GFP expression rate was reduced to 40% of an undisturbed sample. We observed a similar inhibition of GFP expression by D2O in a recombinant Escherichia coli strain, although the inhibitory effect is less pronounced. These results demonstrate the suitability of cell-free systems for quantifying the impact of heavy water on gene expression and establish a platform to further assess the potential therapeutic use of heavy water as antiproliferative agent.
Fakultät für Physik - Digitale Hochschulschriften der LMU - Teil 04/05
Genexpression that is the cellular synthesis of proteins is comprised of the sub-steps tran- scription (mRNA synthesis based on the DNA master), translation (protein synthesis based on the mRNA) and protein folding. Owing to the large number of interactions between individual components this process is very complex in vivo and therefore mathematical modeling is extremely laborious. By means of simpli�ed in vitro model systems individual aspects of cellular gene expression can be studied in detail. Cell-free gene expression denotes the biochemical synthesis of proteins in vitro. Cell-free systems are comprised of the predominant components of the cellular transcription and translation machinery like polymerases, ribosomes, amino acids and nucleotides dissolved in bu�er. These systems are either cellular extracts or are reconstituted from puri�ed components. In this thesis gene expression in a cell-free system was used to develop a quantitative model system of the gene expression kinetics in vitro. To this end techniques were developed that enable reproducible quantitative fuorescence measurements of mRNA and protein synthesized in a cell-free system.
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 04/06
Wed, 26 Sep 2012 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17510/ https://edoc.ub.uni-muenchen.de/17510/1/Wagner_Felicia.pdf Wagner, Felicia ddc:540,
Wed, 1 Jan 1992 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7520/1/cell-free_system_for_assembly_of_transcriptionally_repressed_chromatin_7520.pdf Wu, Chun-Guey; Becker, Peter B.
Sat, 1 Dec 1979 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7339/1/Neupert_Walter_7339.pdf Neupert, Walter; Paluch, Ulrich; Zimmermann, Richard ddc:610, Medizin
ADP/ATP carrier protein was synthesized in heterologous cell-free systems programmed with Neurospora poly(A)-containing RNA and homologous cell-free systems from Neurospora. The apparent molecular weight of the product obtained in vitro was the same as that of the authentic mitochondrial protein. The primary translation product obtained in reticulocyte lysates starts with formylmethionine when formylated initiator methionyl-tRNA (fMet-tRNAfMet) was present. The product synthesized in vitro was released from the ribosomes into the postribosomal supernatant. The evidence presented indicates that the ADP/ATP carrier is synthesized as a polypeptide with the same molecular weight as the mature monomeric protein and does not carry an additional sequence.
Synthesis and transport of mitochondrial proteins were followed in a cell-free homogenate of Neurospora crassa in which mitochondrial translation was inhibited. Proteins synthesized on cytoplasmic ribosomes are transferred into the mitochondrial fraction. The relative amounts of proteins which are transferred in vitro are comparable to those transferred in whole cells. Cycloheximide and puromycin inhibit the synthesis of mitochondrial proteins but not their transfer into mitochondria. The transfer of immunoprecipitable mitochondrial proteins was demonstrated for matrix proteins, carboxyatractyloside-binding protein and cytochrome c. Import of proteins into mitochondria exhibits a degree of specificity. The transport mechanism differentiates between newly synthesized proteins and preexistent mitochondrial proteins, at least in the case of matrix proteins. In the cell-free homogenate membrane-bound ribosomes are more active in the synthesis of mitochondrial proteins than are free ribosomes. The finished translation products appear to be released from the membrane-bound ribosomes into the cytosol rather than into the membrane vesicles. The results suggest that the transport of cytoplasmically synthesized mitochondrial proteins is essentially independent of cytoplasmic translation; that cytoplasmically synthesized mitochondrial proteins exist in an extramitochondrial pool prior to import; that the site of this pool is the cytosol for at least some of the mitochondrial proteins; and that the precursors in the extramitochondrial pool differ in structure or conformation from the functional proteins in the mitochondria.
Sat, 1 Jan 1977 12:00:00 +0100 https://epub.ub.uni-muenchen.de/7319/1/7319.pdf Neupert, Walter; Korb, Harald; Zimmermann, Richard
© 2020-2025 Ivy Podcast Discovery LLC
